Cellular Immunotherapy Market Size, Share & Trends Analysis Report By Therapy Type (CAR T Cell Therapy, Dendritic Cell Therapy), By Indication (B-cell Malignancies, Prostate Cancer), By End-use- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030
Chapter 1. Methodology and Scope
1.1 Market Segmentation
1.1.1 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database
1.3.2 Nova one advisor’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.3.6 List of primary sources
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity flow analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country-wise market estimation using a bottom-up approach
1.7 Global Market: CAGR Calculation
1.8 Research Assumptions
1.9 List of Secondary Sources
1.10 List of Abbreviations
1.11 Objectives
1.11.1 Objective 1
1.11.2 Objective 2
1.11.3 Objective 3
1.11.4 Objective 4
Chapter 2. Executive Summary
2.1 Market Summary
Chapter 3. Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.2 Regulatory framework
3.3 Penetration and Growth Prospect Mapping
3.4 Pipeline Analysis
3.5 Market Dynamics
3.5.1 Market driver analysis
3.5.2 Market restraint analysis
3.6 PESTEL Analysis
Chapter 4. Global Cellular Immunotherapy Market - Segment Analysis, By Therapy Type, 2017 - 2030
4.1 Global Cellular Immunotherapy Market: Therapy Type Movement Analysis
4.2 CAR T Cell Therapy
4.2.1 CAR T Cell Therapy market estimates and forecast, 2017 - 2030
4.3 Dendritic Cell Therapy
4.3.1 Dendritic Cell Therapy market estimates and forecast, 2017 - 2030
4.4 NK Cell Therapy
4.4.1 TIL Therapy market estimates and forecast, 2017 - 2030
4.5 Others
4.5.1 Other market estimates and forecast, 2017 - 2030
Chapter 5. Global Cellular Immunotherapy Market - Segment Analysis, by Indication, 2017 - 2030
5.1 Global Cellular Immunotherapy Market: Indication Movement Analysis
5.2 B-cell Malignancies
5.2.1 B-cell Malignancies market estimates and forecast, 2017 - 2030
5.3 Prostate Cancer
5.3.1 Prostate Cancer market estimates and forecast, 2017 - 2030
5.4 Liver Cancer
5.4.1 Liver Cancer market estimates and forecast, 2017 - 2030
5.5 Renal Cell Carcinoma
5.5.1 Renal Cell Carcinoma market estimates and forecast, 2017 - 2030
5.6 Others
5.6.1 Other market estimates and forecast, 2017 - 2030
Chapter 6. Global Cellular Immunotherapy Market - Segment Analysis, By End Use, 2017 - 2030
6.1 Global Cellular Immunotherapy Market: End Use Movement Analysis
6.2 Hospitals
6.2.1 Hospital market estimates and forecast, 2017 - 2030
6.3 Cancer Institutes
6.3.1 Cancer institute’s market estimates and forecast, 2017 - 2030
6.4 Others
6.4.1 Other market estimates and forecast, 2017 - 2030
Chapter 7. Cellular Immunotherapy Market: Segment Analysis, by Region, 2017 - 2030
7.1 Cellular Immunotherapy Market: Regional Movement Analysis
7.1.1 North America
7.1.1.1 North America market estimates and forecast, 2017 - 2030 USD Million
7.1.1.2 U.S.
7.1.1.2.1 U.S. market estimates and forecast, 2017 - 2030 USD Million
7.1.1.3 Canada
7.1.1.3.1 Canada market estimates and forecast, 2017 - 2030 USD Million
7.1.2 Europe
7.1.2.1 Europe market estimates and forecast, 2017 - 2030 USD Million
7.1.2.2 U.K.
7.1.2.2.1 U.K. market estimates and forecast, 2017 - 2030 USD Million
7.1.2.3 Germany
7.1.2.3.1 Germany market estimates and forecast, 2017 - 2030 USD Million
7.1.2.4 France
7.1.2.4.1 France market estimates and forecast, 2017 - 2030 USD Million
7.1.2.5 Spain
7.1.2.5.1 Spain market estimates and forecast, 2017 - 2030 USD Million
7.1.2.6 Italy
7.1.2.6.1 Italy market estimates and forecast, 2017 - 2030 USD Million
7.1.2.7 Russia
7.1.2.7.1 Russia market estimates and forecast, 2017 - 2030 USD Million
7.1.3 Asia Pacific
7.1.3.1 Asia Pacific market estimates and forecast, 2017 - 2030 USD Million
7.1.3.2 Japan
7.1.3.2.1 Japan market estimates and forecast, 2017 - 2030 USD Million
7.1.3.3 China
7.1.3.3.1 China market estimates and forecast, 2017 - 2030 USD Million
7.1.3.4 India
7.1.3.4.1 India market estimates and forecast, 2017 - 2030 USD Million
7.1.3.5 Australia
7.1.3.5.1 Australia market estimates and forecast, 2017 - 2030 USD Million
7.1.3.5 South Korea
7.1.3.5.1 South Korea market estimates and forecast, 2017 - 2030 USD Million
7.1.4 Latin America
7.1.4.1 Latin America market estimates and forecast, 2017 - 2030 USD Million
7.1.4.2 Brazil
7.1.4.2.1 Brazil market estimates and forecast, 2017 - 2030 USD Million
7.1.4.3 Mexico
7.1.4.3.1 Mexico market estimates and forecast, 2017 - 2030 USD Million
7.1.4.4 Argentina
7.1.4.4.1 Argentina market estimates and forecast, 2017 - 2030 USD Million
7.1.5 Middle East & Africa
7.1.5.1 Middle East & Africa market estimates and forecast, 2017 - 2030 USD Million
7.1.5.2 South Africa
7.1.5.2.1 South Africa market estimates and forecast, 2017 - 2030 USD Million
7.1.5.3 Saudi Arabia
7.1.5.3.1 Saudi Arabia market estimates and forecast, 2017 - 2030 USD Million
7.1.5.5 United Arab Emirates
7.1.5.5.1 United Arab Emirates market estimates and forecast, 2017 - 2030 USD Million
Chapter 8. Global Cellular Immunotherapy Market: Competitive Analysis
8.1 Recent Developments and Impact Analysis, by Key Market Participants
8.1.1 Synergy analysis: Major deals and strategic alliances
8.1.1.1 New Product Launches
8.1.1.2 Mergers and Acquisitions
8.1.1.3 Partnerships & Agreements
8.2 Company Categorization
8.2.1 Innovators
8.2.2 Market Leaders
8.2.3 Emerging Players
8.2.4 Heat Map Analysis
8.3 Company Market Position Analysis
8.4 Vendor Landscape
8.4.1 List of Key Distributors and Channel Partners
8.4.2 List of Potential End Users
8.4.3 Key Company Market Share Analysis, 2021
8.5 Company Market Share/Ranking, 2021
8.5.1 Competitive Dashboard Analysis
8.6 Private Companies
8.6.1 List of Key Emerging Companies
8.6.2 Regional Network Map
8.7 Company Profiles
8.7.1 Bristol-Myers Squibb Company
8.7.1.1 Company overview
8.7.1.2 Financial performance
8.7.1.3 Product benchmarking
8.7.1.4 Strategic initiatives
8.7.2 F. Hoffmann-La Roche Ltd.
8.7.2.1 Company overview
8.7.2.2 Financial performance
8.7.2.3 Product benchmarking
8.7.2.4 Strategic initiatives
8.7.3 Merck KGaA
8.7.3.1 Company overview
8.7.3.2 Financial performance
8.7.3.3 Product benchmarking
8.7.3.4 Strategic initiatives
8.7.4 GlaxoSmithKline plc.
8.7.4.1 Company overview
8.7.4.2 Financial performance
8.7.4.3 Product benchmarking
8.7.4.4 Strategic initiatives
8.7.5 AstraZeneca
8.7.5.1 Company overview
8.7.5.2 Financial performance
8.7.5.3 Product benchmarking
8.7.5.4 Strategic initiatives
8.7.6 Pfizer Inc.
8.7.6.1 Company overview
8.7.6.2 Product benchmarking
8.7.6.3 Strategic initiatives
8.7.7 Gilead Sciences Inc. (Kite Pharma)
8.7.7.1 Company overview
8.7.7.2 Financial performance
8.7.7.3 Product benchmarking
8.7.8 Dendreon Pharmaceuticals LLC
8.7.8.1 Company overview
8.7.8.2 Financial performance
8.7.8.3 Product benchmarking
8.7.8.4 Strategic initiatives
8.7.9 Novartis AG
8.7.9.1 Company overview
8.7.9.2 Financial performance
8.7.9.3 Product benchmarking
8.7.9.4 Strategic initiatives
8.7.10 Celyad
8.7.10.1 Company overview
8.7.10.2 Financial performance
8.7.10.3 Product benchmarking
8.7.10.4 Strategic initiatives
8.7.11 Adicet Bio, Inc.
8.7.11.1 Company overview
8.7.11.2 Financial performance
8.7.11.3 Product benchmarking
8.7.11.4 Strategic initiatives